BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?

BioHarvest Sciences Inc. BHST shares ended the last trading session 5.2% higher at $5.90. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.1% loss over the past four weeks.The rise in share price is attributable to positive investor sentiment around the company’s proprietary technology platform to grow plant-based molecules, without the need to grow the underlying plant.This company is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of +57.1%. Revenues are expected to be $7.75 million, up 45.1% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For BioHarvest Sciences Inc., the consensus EPS estimate for the quarter has been revised 66.7% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on BHST going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>BioHarvest Sciences Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Apellis Pharmaceuticals, Inc. APLS, closed the last trading session 0.5% lower at $19.33. Over the past month, APLS has returned -21.3%.For Apellis Pharmaceuticals, the consensus EPS estimate for the upcoming report has changed +0.6% over the past month to -$0.35. This represents a change of +35.2% from what the company reported a year ago. Apellis Pharmaceuticals currently has a Zacks Rank of #3 (Hold).7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioHarvest Sciences Inc. (BHST): Free Stock Analysis Report Apellis Pharmaceuticals, Inc. (APLS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks